Jul 29,2020

Landmark Randomized Controlled Trial Demonstrates Efficacy of Daylight™ Digital Therapeutic in Improving Anxiety

The University of Oxford’s Sleep & Circadian Neuroscience Institute, and Big Health, today announced publication of a randomized controlled trial (RCT) assessing the efficacy and safety of Big Health’s Daylight product in improving symptoms of Generalized Anxiety Disorder (GAD), in the journal Depression and Anxiety. The study found that Daylight significantly reduced symptoms of anxiety in trial participants, as compared to the control group at six weeks after intervention. By week 10 follow-up, 71% of Daylight users in the study achieved remission of GAD, as compared to 33% of those in the control group.

CLINICAL STUDY

#cbt

View Analyst & Ambassador Comments
Go to original news
Jul 11,2019

How digital therapeutic company Omada Health has taken a cue from life sciences

CEO Sean Duffy discusses clinical validation, digital therapeutics and the new opportunity for a digital provider.

View Analyst & Ambassador Comments
Go to original news
Feb 06,2019

Big Health follows up Sleepio with Daylight, an app for anxiety

Big Health, the London and San Francisco-based digital health app company behind CBT-based sleep app Sleepio, has released its second app, Daylight, which is focused on combating worry and anxiety. Like Sleepio, the app is based on cognitive behavioral therapy. It was developed by a group of creatives the company describes as "leading podcast producers, filmmakers, designers and animators, including veterans of Pixar and NPR’s Radiolab", with scientific support from Boston University, University of California, Los Angeles, University of Oxford and University of Texas, Austin.

PRODUCT

#mobile app

#cbt

View Analyst & Ambassador Comments
Go to original news
Jul 28,2021

CEO of digital therapeutics business Freespira talks about its approach to anxiety disorders

Freespira CEO Dean Sawyer said the company's FDA cleared digital therapeutic is the first that’s proven to significantly reduce or eliminate symptoms of panic attacks, panic disorder, and PTSD, in a single, 28-day treatment episode. Sawyer provides an overview of how Freespira is treating anxiety disorders with an FDA cleared digital therapeutic.

PRODUCT
View Analyst & Ambassador Comments
Go to original news
Mar 19,2021

Digital therapeutics company Happify Health secures $73M

Happify Health, a startup building digital therapeutics for people with chronic diseases, raised $73 million in new funding. The investments were led by Deerfield Management Company and included participation from Omega Capital Partners, ION Crossover Partners and existing investors. The fresh capital is part of a new series D and other "related financing," the company said.

FUNDING SERIES D
View Analyst & Ambassador Comments
Go to original news
Oct 15,2021

Scotland offers access to Big Health's DTx for anxiety, insomnia

Scotland is making a cognitive behavioral therapy app for anxiety and insomnia available to all adults in the country, marking a major validation of digital therapeutics to treat behavioral health conditions. Scotland's National Health Service (NHS) will offer national access to products from digital therapeutic maker Big Health at no cost to the user. About 5 million people will be eligible for access to Sleepio, the company’s app to treat insomnia with cognitive behavioral therapy, and Daylight, which is focused on combating worry and anxiety.

PRODUCT

#reimbursement

#mobile app

#cbt

View Analyst & Ambassador Comments
Go to original news
Oct 17,2021

Review: We test new sleep and anxiety therapies being offered on the NHS in Scotland

A review on the user experience for the Sleepio and Daylight solutions from Big Health is provided, after the move by the Scottish Government to make the programmes available on the NHS.

PRODUCT

#mobile app

View Analyst & Ambassador Comments
Go to original news
Nov 11,2021

AppliedVR scores $36M for virtual reality pain management

AppliedVR, developer of virtual reality therapeutics, has scooped up $36 million in Series B funding months after it closed a Series A round. The Series B, which included investments from F-Prime Capital, JAZZ Venture Partners, Sway Ventures and SVB Ventures, brought the company’s total raise to $71 million. AppliedVR creates virtual reality technology for healthcare applications, with platforms in its pipeline for chronic pain management, acute postoperative pain and anxiety.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Dec 10,2021

HypnoVR raises €4.5M in Series A

French digital therapeutics firm HypnoVR has raised €4.5 million in Series A funding for its virtual reality-based medical hypnosis solution for pain and anxiety. The round was led by Theodorus, the Banque des Territoires operating for the French state as part of the Investments for the Future Programme, Akiles and Capital Grand Est via Alsace Création. HypnoVR will use the funds to accelerate its international roll-out and extend the scope of application of its solution.

FUNDING SERIES A

#virtual reality

View Analyst & Ambassador Comments
Go to original news
Subscribe to ANXIETY